Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | sunitinib (Sutent®) | ||
| Formulation | capsule | ||
| Reference number | 390 | ||
| Indication | Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. Experience with sunitinib as first-line treatment is limited |
||
| Company | Pfizer Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 1111 | ||
| NMG meeting date | 20/07/2011 | ||
| AWMSG meeting date | 14/09/2011 | ||
| Ratification by Welsh Government | 11/10/2011 | ||
| Date of issue | 13/10/2011 | ||
| NICE guidance | TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (external website - opens in new window) |
||